Status:
COMPLETED
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
i3 Innovus
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who ...
Eligibility Criteria
Inclusion
- At least 6 month history of GERD symptoms
- Treated with unchanged optimized PPI treatment for any GERD indication during the last 4 weeks before enrollment
- Remaining GERD symptoms despite optimized PPI treatment
- Able to read and write in French, and able to comply with study requirements
Exclusion
- Patients that have not experienced any GERD symptom improvement at all during PPI treatment
- Involvement in the planning or conduct of the study
- Involvement in any other observational study or in any clinical study at the time of this study or during the last 6 months
- Prior surgery of the upper GI tract
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT00842855
Start Date
February 1 2009
End Date
November 1 2010
Last Update
February 7 2011
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bandol, France
2
Research Site
Beaumont-sur-Oise, France
3
Research Site
Beausoleil, France
4
Research Site
Behren-lès-Forbach, France